Promethera Biosciences
PrivateLast Round
Corporate Funding
Jun 30, 2021
Total Funding Raised
$134.6M
Company Overview
Promethera Biosciences operates in Healthcare & Life Sciences and is based in Mont-Saint-Guibert. Its latest recorded funding round was a Series D round in May 2019.
Promethera Biosciences is a biotechnology company that develops innovative cell-based therapies for the treatment of severe liver diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Promethera Biosciences Comparables
Compare Promethera Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| GoLiver Therapeutics | 85% | |
| Morphocell Technologies | 82% | |
| HepaTx Corporation | 78% |
For institutional investors. Book with your work email.
Promethera Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Corporate Funding | Jun 30, 2021 | ||||
| Series D | May 7, 2019 | ||||
| Series C Extension | Oct 28, 2016 | ||||
| Series C | Nov 25, 2014 | ||||
| Series B | Mar 28, 2012 | ||||
Series A | Nov 9, 2009 |
For institutional investors. Book with your work email.
Promethera Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Federal Holding and Investment Company | Series C |
| Sopartec | Series A, Corporate Funding, Series B |
| SMS Investments | Series C, Series C Extension |
| LRM | Series A |
| Korea Investment Partners | Series D |
| Mitsui Global Investment | Series D, Series C, Series B |
| Shinsei Capital Partners | Series D |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 30, 2021
$24M raised from Fund+, Nivelinvest, Sambrinvest, and Sopartec.
- May 7, 2019
$53M round led by Innovation Fund and Itochu Corporation.
For institutional investors. Book with your work email.
Promethera Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Promethera Biosciences's valuation, stock price, and market status.
Is Promethera Biosciences a public or private company?
Promethera Biosciences is a private company.
What is the current stock price of Promethera Biosciences?
Promethera Biosciences is a private company, so its shares have no public market price. Caplight tracks Promethera Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Promethera Biosciences worth (valuation)?
Valuation information for Promethera Biosciences is not publicly available.
Can I buy Promethera Biosciences stock?
Promethera Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Promethera Biosciences's last funding round?
Promethera Biosciences's most recent funding round was Corporate Funding on June 30, 2021.
Who are the main investors in Promethera Biosciences?
Key investors in Promethera Biosciences include Shinsei Capital Partners, Vesalius Biocapital Partners, Pegasus Tech Ventures.
Will Promethera Biosciences IPO soon?
No public IPO plans have been announced for Promethera Biosciences.
How can I track Promethera Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Promethera Biosciences's shares on secondary markets.